HER2 test showdown: which lab method is best for chinese cancer patients?

NCT ID NCT07404202

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which helps guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer cervical cancer endometrial cancer non-small cell lung carcinoma ovarian cancer urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAN-TUMOR(NSCLC, GYN CANCERS, BTC AND UC)

Contacts and locations

Locations

Research Site
RECRUITING

Beijing, China
Research Site
WITHDRAWN

Changsha, China
Research Site
RECRUITING

Chengdu, China
Research Site
RECRUITING

Guangzhou, China
Research Site
WITHDRAWN

Guangzhou, China
Research Site
RECRUITING

Haerbin, China
Research Site
RECRUITING

Jinan, China
Research Site
RECRUITING

Nantong, China
Research Site
WITHDRAWN

Shanghai, China
Research Site
RECRUITING

Shanghai, China
Research Site
RECRUITING

Shenyang, China
Research Site
WITHDRAWN

Suzhou, China
Research Site
RECRUITING

Ürümqi, China
Research Site
RECRUITING

Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.